Vlado Perkovic's Publications

• Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

  Journal articles

  2021

  Kidney International

• Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program

  Journal articles

  2021

  ESC Heart Failure

• The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals

  Journal articles

  2021

  Kidney International

• Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

  Journal articles

  2021

  American Heart Journal

• The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes

  Journal articles

  2021

  Diabetes, Obesity and Metabolism

• Hemodialysis Use and Practice Patterns: An International Survey Study

  Journal articles

  2021

  American Journal of Kidney Diseases

• Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor

  Journal articles

  2021

  Kidney International Reports

• Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial

  Journal articles

  2021

  Diabetes, Obesity and Metabolism

• An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials

  Journal articles

  2021

  International Journal of Cardiology

• Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

  Journal articles

  2021

  Diabetes, Obesity and Metabolism

• Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: The CARMELINA randomized controlled trial

  Journal articles

  2021

  Clinical Kidney Journal

• Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria a credence secondary analysis

  Journal articles

  2021

  Clinical Journal of the American Society of Nephrology

• Forever starts now: Effects of glucose-lowering therapies on acute kidney injury

  Journal articles

  2021

  Clinical Journal of the American Society of Nephrology

• Choice of endpoint in kidney outcome trials: Considerations from the EMPA-REG OUTCOMEsupVRsup trial

  Journal articles

  2021

  Nephrology Dialysis Transplantation

• Sglt2 inhibition for ckd and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the national kidney foundation

  Conference Papers

  2021

  Diabetes

• Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

  Journal articles

  2021

  American Journal of Kidney Diseases

• Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis

  Journal articles

  2021

  Diabetes, Obesity and Metabolism

• Sodium-glucose cotransporter 2 inhibition: Which patient with chronic kidney disease should be treated in the future?

  Journal articles

  2021

  Nephrology Dialysis Transplantation

• The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Trial

  Conference Papers

  2021

  JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

• The TESTING Study: Steroids vs. Placebo in High Risk IgA Nephropathy

  Conference Papers

  2021

  JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

• Effects of Canagliflozin (CANA) on Kidney Outcomes: Pooled Analyses from the CANVAS Program and CREDENCE

  Conference Papers

  2021

  JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

• IL-6 Inhibitor Ziltivekimab Increases Serum Hemoglobin and Iron Biomarkers in Patients with CKD Stage 3-5: A RESCUE Trial Analysis

  Conference Papers

  2021

  JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

• ASCEND Program: Efficacy and Safety from ASCEND-D and -ND and Overall MACE Finding

  Conference Papers

  2021

  JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

• Circulating Metabolites to Predict Renal Outcomes in CANVAS Type 2 Diabetes Mellitus Population

  Conference Papers

  2021

  JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

• ASCEND Program: Efficacy and Safety from ASCEND-D and -ND and Overall MACE Finding

  Journal articles

  2021

  Journal of the American Society of Nephrology

• Effects of Canagliflozin (CANA) on Kidney Outcomes: Pooled Analyses from the CANVAS Program and CREDENCE

  Journal articles

  2021

  Journal of the American Society of Nephrology